ReviewFrontiers in oncology2021
Recurrent Intrahepatic Cholangiocarcinoma - Review.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histo-molecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature.Journal of gastrointestinal cancer · 2024Pooled it
- Article
- Metabolic and Inflammatory Risk Stratification in Resected Cholangiocarcinoma: A Retrospective Exploratory Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Three-Tiered Nodal Staging System Improves Prognostic Utility for Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.JCO precision oncology · 2026Review
- Review
- Circulating tumor DNA-guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities.World journal of surgical oncology · 2026Review
- A novel interpretable machine learning framework integrating clinicopathological and radiomic features for early recurrence prediction in mass-forming intrahepatic cholangiocarcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Prognostic value of preoperative serum ferritin in cholangiocarcinoma patients.Scientific reports · 2025Article
- Article
- PTP4A1 promotes intrahepatic cholangiocarcinoma development and progression by interacting with PTEN and activating the PI3K/AKT/GSKα axis.Oncology reports · 2025Article
- Center Experience Is Associated With Improved Survival in Liver Transplantation for Hilar Cholangiocarcinoma: A Retrospective Study.Transplantation direct · 2025Article
- Three-dimensional genome architecture in intrahepatic cholangiocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Article
- Safety and efficacy of pemigatinib in patients with cholangiocarcinoma: a systematic review.Journal of gastrointestinal oncology · 2025Review
- Prognostic implications of tumor histology and microenvironment in surgically resected intrahepatic cholangiocarcinoma: a single institutional experience.Virchows Archiv : an international journal of pathology · 2025Article
- Article
- The prognostic value of the preoperative albumin-to-fibrinogen ratio in patients with intrahepatic cholangiocarcinoma: a multicenter retrospective propensity score matching analysis.Frontiers in oncology · 2025Article
- Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.